EORTC评分系统在非肌层浸润性膀胱癌预后评估中的应用

Application of European Organization of Research and Treatment of Cancer scoring system in the evaluation of prognosis of patients with non-muscle invasive bladder cancer

目的:探讨欧洲癌症研究与治疗组织(EORTC)建议的膀胱癌预后评分系统在非肌层浸润性膀胱癌(NMIBC)患者预后评估中的应用价值。方法:选取2008年1月至2014年1月在广西医科大学第一附属医院行经尿道膀胱肿瘤切除术(TURBT)的107例NMBIC患者,根据EORTC评分标准对患者的预后风险进行评分,并按术后复发和进展评分进行分组(复发总分分为4组:0分组、1~4分组、5~9分组、10~17分组;进展总分分为0分组、2~6分组、7~13分组、14~23分组)。随访1年和5年后,将各组的实际复发率和进展率分别与EORTC评分系统的预测值进行比较。结果:各组1年实际复发率和5年实际复发率分别与EORTC风险评分系统的1年预测复发率和5年预测复发率比较,差异均无统计学意义(均P>0.05)。各组1年实际进展率和5年实际进展率分别与EORTC评分系统的1年预测进展率和5年预测进展率比较,差异均无统计学意义(均P>0.05)。结论:EORTC评分系统能准确预测NMIBC患者的预后情况,值得临床推广应用。

Objective： To assess the clinical value of European Organization of Research and Treatment of Cancer （EORTC） scoring system for the evaluation of prognosis of patients with non-muscle invasive blad- der cancer （NMIBC）. Methods： 107 patients with NMIBC undergoing transurethral resection of bladder tumor （TUR-BT） in our hospital from January 2008 to January 2014 were selected and divided into recur-rence group and progress group according to EORTC prognostic risk scores. After one-year and five-year follow-up, the actual recurrence rate andprogress rate were compared with the predictive values based on EORTC scoring system. Results： The ac- tual one- and five-year recurrence rates as well as the actual one-and five-year progress rates were similar to the predictive values based on EORTC scoring system （ P〉0.05）. Conclusion： EORTC scoring system could predict the prognosis of patients with NMIBC